{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:39:56Z","timestamp":1792809596596,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["NMRPG8L6121"],"award-info":[{"award-number":["NMRPG8L6121"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8N0981"],"award-info":[{"award-number":["CMRPG8N0981"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"DOI":"10.1007\/s12072-026-11166-5","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:39:05Z","timestamp":1792762745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher relapse rate after stopping tenofovir alafenamide compared with\u00a0entecavir; but not tenofovir disoproxil fumarate in HBeAg-positive patients"],"prefix":"10.1007","author":[{"given":"Kuan-Hung","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-8133","authenticated-orcid":false,"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"11166_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284\u2013306","journal-title":"Hepatology"},{"key":"11166_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","volume":"15","author":"JH Kao","year":"2021","unstructured":"Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021;15:833\u2013851","journal-title":"Hepatol Int"},{"key":"11166_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83:502\u2013583","journal-title":"J Hepatol"},{"key":"11166_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/HEP.0000000000001549","volume":"83","author":"MG Ghany","year":"2026","unstructured":"Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, et al. AASLD\/IDSA practice guideline on treatment of chronic hepatitis B. Hepatology. 2026;83:1020\u20131095","journal-title":"Hepatology"},{"key":"11166_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s12072-013-9440-5","volume":"7","author":"CH Chen","year":"2013","unstructured":"Chen CH, Hu TH, Hung CH, Lu SN, Wang JH, Chang MH, et al. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-na\u00efve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatol Int. 2013;7:832\u2013843","journal-title":"Hepatol Int"},{"key":"11166_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","volume":"5","author":"A Ono","year":"2012","unstructured":"Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t)ide-na\u00efve chronic hepatitis B patients. J Hepatol. 2012;5:508\u2013514","journal-title":"J Hepatol"},{"key":"11166_CR7","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/hep.26549","volume":"58","author":"WJ Jeng","year":"2013","unstructured":"Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58:1888\u20131896","journal-title":"Hepatology"},{"key":"11166_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","volume":"61","author":"CH Chen","year":"2014","unstructured":"Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014;61:515\u2013522","journal-title":"J Hepatol"},{"key":"11166_CR9","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2015;13:1984\u20131992","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11166_CR10","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","volume":"14","author":"WJ Jeng","year":"2016","unstructured":"Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN, et al. Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patients. Clin Gastroenterol Hepatol. 2016;14:1813\u20131820","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11166_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.15053","volume":"49","author":"MT Kuo","year":"2019","unstructured":"Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther. 2019;49:218\u2013228","journal-title":"Aliment Pharmacol Ther"},{"key":"11166_CR12","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","volume":"18","author":"SM Chiu","year":"2020","unstructured":"Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, et al. Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy. Clin Gastroenterol Hepatol. 2020;18:2989\u20132997","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11166_CR13","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/infdis\/jiab596","volume":"225","author":"CH Chen","year":"2022","unstructured":"Chen CH, Peng CY, Kuo YH, Hu TH, Hung CH, Wang JH, et al. Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in hepatitis B e antigen-positive patients. J Infect Dis. 2022;225:1974\u20131981","journal-title":"J Infect Dis"},{"key":"11166_CR14","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.14309\/ajg.0000000000003324","volume":"120","author":"HW Fang","year":"2025","unstructured":"Fang HW, Jeng WJ, Hu TH, Wang JH, Hung CH, Lu SN, et al. Higher relapse rate in HBeAg-negative patients after cessation of tenofovir alafenamide compared with\u00a0entecavir\u00a0or tenofovir disoproxil fumarate. Am J Gastroenterol. 2025;120:2567\u20132575","journal-title":"Am J Gastroenterol"},{"key":"11166_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u2013561","journal-title":"Hepatol Int"},{"key":"11166_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/00365521.2018.12027892","volume":"38","author":"CM Lee","year":"2003","unstructured":"Lee CM, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol. 2003;38:95\u2013101","journal-title":"Scand J Gastroenterol"},{"key":"11166_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/oxfordjournals.aje.a116813","volume":"138","author":"G Maldonado","year":"1993","unstructured":"Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923\u2013936","journal-title":"Am J Epidemiol"},{"key":"11166_CR18","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265\u20132681","journal-title":"Stat Med"},{"key":"11166_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150\u2013161","journal-title":"Pharm Stat"},{"key":"11166_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/liv.13346","volume":"37","author":"DK Wong","year":"2017","unstructured":"Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37:995\u20131001","journal-title":"Liver Int"},{"key":"11166_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testoni","year":"2019","unstructured":"Testoni B, Lebosse F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615\u2013625","journal-title":"J Hepatol"},{"key":"11166_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","volume":"67","author":"K Murata","year":"2018","unstructured":"Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, et al. Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut. 2018;67:362\u2013371","journal-title":"Gut"},{"key":"11166_CR23","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.jhep.2023.08.009","volume":"80","author":"X Yu","year":"2024","unstructured":"Yu X, Long J, Xie Y, Zhang J, Su Z. Immunomodulatory effects of tenofovir disoproxil fumarate and entecavir in treating HBV infection. J Hepatol. 2024;80:e123\u2013e125","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11166-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11166-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11166-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:01:47Z","timestamp":1792807307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11166-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":23,"alternative-id":["11166"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11166-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"12 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Cheng-Yuan Peng has served as an advisory committee member for AbbVie, BMS, Gilead, and MSD. Chien-Hung Chen, Kuan-Hung Wan, Yuan-Hung Kuo, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}